Abcellera Biologics Inc
F:8QQ

Watchlist Manager
Abcellera Biologics Inc Logo
Abcellera Biologics Inc
F:8QQ
Watchlist
Price: 3.106 EUR 0.65% Market Closed
Market Cap: 913.3m EUR

Wall Street
Price Targets

8QQ Price Targets Summary
Abcellera Biologics Inc

Wall Street analysts forecast 8QQ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 8QQ is 8.244 EUR with a low forecast of 5.811 EUR and a high forecast of 13.808 EUR.

Lowest
Price Target
5.811 EUR
87% Upside
Average
Price Target
8.244 EUR
165% Upside
Highest
Price Target
13.808 EUR
345% Upside
Abcellera Biologics Inc Competitors:
Price Targets
2269
WuXi Biologics (Cayman) Inc
24% Upside
MXCT
MaxCyte Inc
302% Upside
HYFT
Immunoprecise Antibodies Ltd
140% Upside
MCAP
MedCap AB (publ)
15% Upside
300759
Pharmaron Beijing Co Ltd
28% Upside
FLB
Fluidigm Corp
8% Downside
DIM
Sartorius Stedim Biotech SA
19% Upside
INNOVACAP
Innova Captab Ltd
16% Upside

Revenue
Forecast

Revenue Estimate
Abcellera Biologics Inc

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 4 years is 50%.

20%
Past Growth
50%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Abcellera Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Abcellera Biologics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is 8QQ's stock price target?
Price Target
8.244 EUR

According to Wall Street analysts, the average 1-year price target for 8QQ is 8.244 EUR with a low forecast of 5.811 EUR and a high forecast of 13.808 EUR.

What is Abcellera Biologics Inc's Revenue forecast?
Projected CAGR
50%

For the last 5 years the compound annual growth rate for Abcellera Biologics Inc's revenue is 20%. The projected CAGR for the next 4 years is 50%.

Back to Top